share_log

微芯生物(688321.SH):西奥罗尼III期试验已结束,正在推进Pre-NDA沟通工作

Shenzhen Chipscreen Biosciences (688321.SH): Phase III trial of Xylorinib has been completed, and pre-NDA communication is underway.

Gelonghui Finance ·  Jul 5 03:57

Chipscreen Biosciences (688321.SH) stated on the investor interaction platform on July 5th that the Phase III trial of Sirotninib has ended and is currently advancing Pre-NDA communication work.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment